Xenon Pharmaceuticals (XENE) Misses Q2 EPS by 2c

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q2 EPS of ($0.41), $0.02 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $20 thousand versus the consensus estimate of $250 thousand.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Intel to report later this week, but analysts flag weakness in chipmaking unit
• Equity Residential (EQR) Tops Q1 EPS by 44c; offers guidance